Source-based drug interaction information. Detailed information is available with page access.<\/p>","protected":true},"excerpt":{"rendered":"
Source-based drug interaction information. Detailed information is available with page access.<\/p>","protected":true},"ism_preview":{"drugs":[{"title":"Nilotinib","url":"https:\/\/www.ortaakarsu.net\/?ism_drug=nilotinib","facts":[{"label":"Active ingredient \/ generic name","value":"nilotinib"},{"label":"ATC code","value":"L01EA03"},{"label":"Administration route","value":"Oral"}]},{"title":"Tegretol CR 200 mg (Turkish record)","url":"https:\/\/www.ortaakarsu.net\/?ism_drug=tegretol-cr-200-mg","facts":[{"label":"Active ingredient \/ generic name","value":"Karbamazepin"},{"label":"ATC code","value":"N03AF01"}]}],"record":[{"label":"Record type","value":"Published interaction record"},{"label":"Source record version","value":"DailyMed TASIGNA SPL v42; effective 2025-12-16; checked 2026-11-04; 7.1 and 12.3"}],"sources":[{"label":"TASIGNA U.S. prescribing information (DailyMed)","url":"https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=6093952a-5248-45cb-ad17-33716a411146"},{"label":"FDA: clinical examples of drugs interacting with CYP enzymes and transporter systems","url":"https:\/\/www.fda.gov\/drugs\/drug-interactions-labeling\/healthcare-professionals-fdas-examples-drugs-interact-cyp-enzymes-and-transporter-systems"}],"reviewed_at":"2026-11-04"},"ism_access":{"required":true,"resource_key":"pair:36151","available":true}}